scholarly journals Vasoactive neuropeptides and Alzheimer’s disease: a systematic review focusing on calcitonin gene-related peptide

2021 ◽  
Vol 20 (4) ◽  
pp. 1059-1065
Author(s):  
Giulio Papiri ◽  
Simona Luzzi ◽  
Matteo Marcucci ◽  
Arianna Vignini
Keyword(s):  
Systematic Review ◽  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Calcitonin Gene Related Peptide ◽  
Related Peptide ◽  
Calcitonin Gene

scholarly journals Calcitonin gene-related peptide (CGRP): A novel target for Alzheimer's disease

2017 ◽  
Vol 23 (6) ◽  
pp. 457-461 ◽  
Author(s):  
Yogendra Singh ◽  
Gaurav Gupta ◽  
Birendra Shrivastava ◽  
Rajiv Dahiya ◽  
Juhi Tiwari ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Calcitonin Gene Related Peptide ◽  
Related Peptide ◽  
Calcitonin Gene ◽  
Novel Target

scholarly journals Calcitonin gene-related peptide and pain: a systematic review

2017 ◽  
Vol 18 (1) ◽  
Author(s):  
Wendy Sophie Schou ◽  
Sait Ashina ◽  
Faisal Mohammad Amin ◽  
Peter J. Goadsby ◽  
Messoud Ashina
Keyword(s):  
Systematic Review ◽  
Calcitonin Gene Related Peptide ◽  
Related Peptide ◽  
Calcitonin Gene

scholarly journals Effects of Anti-Calcitonin Gene-Related Peptide for Migraines: A Systematic Review with Meta-Analysis of Randomized Clinical Trials

2019 ◽  
Vol 20 (14) ◽  
pp. 3527 ◽  
Author(s):  
I-Hsin Huang ◽  
Po-Chien Wu ◽  
En-Yuan Lin ◽  
Chien-Yu Chen ◽  
Yi-No Kang
Keyword(s):  
Systematic Review ◽  
Clinical Trials ◽  
Randomized Clinical Trials ◽  
Response Rate ◽  
Meta Analysis ◽  
Calcitonin Gene Related Peptide ◽  
Related Peptide ◽  
Long Term Effect ◽  
Calcitonin Gene ◽  
Quantitative Synthesis

We aimed to evaluate the response rate of migraines by using anti-calcitonin gene-related peptide (anti-CGRP) for patients with migraines. We searched three main medical databases up to 29 March 2019. No restriction on language and publication time were applied. Eligible trials included randomized clinical trials investigating a 50%, 75%, and 100% response rate of migraine patients after anti-CGRP intervention. The collected data were dichotomous, and risk ratios (RRs) with a 95% confidence interval (CI) were used to present the quantitative synthesis results. The systematic review identified 16 eligible randomized clinical trials (RCTs) with 9439 patients. Eight of the 16 trials with 2516 patients reported a 50% response rate, and the pooled results showed a significant benefit from anti-CGRP. However, the effects seem to gradually reduce from the first month (RR 1.99, 95% CI 1.59 to 2.49) to the third month (RR 1.48, 95% CI 1.26 to 1.75) of treatment. The magnitude of effect was influenced by the type of anti-CGRP, according to the test for differences between subgroups (I-square = 53%). The funnel plots and Egger’s tests did not show serious small study effects in the results. In conclusion, the current evidences confirmed that anti-CGRP treatment can reduce migraine pain in the short term (within three months), but the long-term effect should be investigated in the future. Moreover, its effects may be influenced by the type and dose of anti-CGRP. Therefore, future studies should make direct comparisons among anti-CGRP medications.

Sign in / Sign up

Export Citation Format

Share Document